Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:29 PM
Ignite Modification Date:
2025-12-24 @ 6:29 PM
NCT ID:
NCT06175468
Eligibility Criteria:
Inclusion Criteria:
* Subjects who meet the criteria guideline in the "Seasonal Influenza Prevention and Control Manual" recommended by the Taiwan Centers for Disease Control, or are determined by the investigator to have mild symptoms of COVID-19, including fever, sore throat, cough, and fatigue.
* Subjects who have had a fever (body temperature ≥37.5°C and ≤39°C) before their initial dose.
* Throat pain intensity score \>30 points during the screening period.
* Cough severity score \>3 points during the screening period.
* Fatigue level score \>30 points during the screening period.
* Able to perform activities of daily living and aged 20 weeks or older.
* Duration of illness ≤24 hours.
* Obtained informed consent from the subject and signed the informed consent form.
Exclusion Criteria:
* Subject has used other medications for this condition (including cold medicine, antibiotics, antiviral drugs, and similar traditional Chinese medicines) within the 24 hours prior to screening, or is determined by the investigator to require the use of antibiotics or COVID-19 anti-virus drugs.
* Subject has used corticosteroids or NSAIDs for an extended period within the four weeks prior to screening.
* Subject has had poorly controlled chronic diseases in the past five years, including cardiovascular, respiratory, gastrointestinal, immune-related conditions, or mental health disorders (as determined by the investigator).
* Subject has had chronic bronchitis, streptococcal pharyngitis, herpetic pharyngitis, or pneumonia within the past two years or at the time of screening (as determined by the investigator).
* Subject is allergic to the investigational drug or its components.
* Women who are pregnant, breastfeeding, or planning to become pregnant.
* Subject has participated in other drug clinical trials within the 90 days prior to screening.
* The investigator evaluates the subject unsuitable for inclusion in the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT06175468
Study Brief:
Protocol Section:
NCT06175468